Vancouver, CANADA--YourWay Cannabis Brands Inc. (CSE: YOUR) (the "Company") announced today that, it anticipates it may be delayed in filing its unaudited interim financial statements for the three months ended March 31, 2022 (the "Q1 Financial Statements"), the related management's discussion and analysis and CEO and CFO certifications (collectively, the "Q1 Filings") by the regulatory filing deadline of May 30, 2022 (the "Filing Deadline") in accordance with National Instrument 51-102 – Continuous Disclosure Obligations. The potential late filing is the result of a number of factors, including (i) the complexity associated with a change of the Company's auditors which took effect on December 6, 2021; (ii) changes in the personnel of the Company requiring additional time to support the auditors; and (iii) further to the Company's press release dated May 2, 2022 and May 10, 2022, the related delay and associated complexities with respect to the completion of the Company's audited annual consolidated financial statements for the year ended December 31, 2021. The Company will work diligently to complete the Q1 Financial Statements and anticipates that, subject to current conditions remaining the same, it will require approximately three additional weeks to complete the process of preparing the Q1 Filings and in any event will use its best efforts to complete the process within the next two months.
As a result of the anticipated delay in filing the Q1 Filings, the Company has applied to the British Columbia Securities Commission, as principal regulator of the Company, to request a management cease trade order (the "MCTO") be issued in accordance with National Policy 12-203 - Management Cease Trade Orders ("NP 12-203"), assuming that the Company's general "failure to file" cease trade order (the "CTO") pursuant to National Policy 11-207 – Failure to File Cease Trade Orders and Revocations in Multiple Jurisdictions dated May 9, 2022 has been revoked before the Filing Deadline.
During the period in which the MCTO is in effect, the general investing public will continue to be able to trade in the Company's common shares listed on the Canadian Securities Exchange. However, for the duration of the MCTO, the Company's Chief Executive Officer and Chief Financial Officer will not be able to trade in the Company's common shares, nor will the Company be able to, directly or indirectly, issue securities to or acquire securities from an insider or employee of the Company except in accordance with legally binding obligations to do so existing as of the Filing Deadline. The Company has also imposed an insider trading blackout pending filing of the Q1 Filings. The Company confirms that it will comply with the alternative information guidelines set forth in NP 12-203 for so long as it remains in default of the requirement to file the Q1 Filings. The Company is not subject to any insolvency proceedings. If granted, the MCTO will remain in effect until the Company files the Q1 Filings or the MCTO is otherwise revoked or varied.